Table 1 Demographic and treatment-related characteristics of patients with vs. without adverse long-term quality of life (QoL) scores
adverse long-term urinary QoL | adverse long-term bowel QoL | |||
|---|---|---|---|---|
yes (n = 261) | no (n = 35) | yes (n = 264) | no (n = 32) | |
patient age/years median (range) | 72 (51-83) | 71 (45-84) | 71 (51-82) | 72 (45-84) |
% fraction dose 1.8 Gy | 69% | 72% | 72% | 72% |
% total dose 72 Gy | 54% | 56% | 59% | 55% |
prostate volume/cc median (range) | 40 (18-107) | 39 (11-151) | 36 (14-107) | 40 (11-151) |
% NHT | 34% | 32% | 38% | 32% |
PTV/cc median (range) | 338 (212-529) | 330 (169-631) | 339 (117-517) | 330 (177-517) |
bladder volume/cc median (range) | 220 (54-657) | 192 (14-806) | 181 (82-657) | 194 (14-806) |
rectum volume/cc median (range) | 102 (43-295) | 97 (28-401) | 93 (38-295) | 98 (28-401) |
AUC for bladder/% median (range) | 37 (12-69) | 41 (7-98) | 35 (7-78) | 41 (7-98) |
bladder volume within 90% isodose*/% | 20 (5-46) | 21 (2-64) | 20 (3-54) | 22 (2-57) |
AUC for rectum/% median (range) | 52 (33-77) | 51 (19-84) | 47 (23-70) | 52 (19-84) |
rectum volume within 90% isodose*/% | 27 (6-64) | 28 (6-60) | 24 (12-50) | 28 (6-64) |